Vergoeding 2019-2023 voor ATC-subgroep L01EB : Egfr-tyrosinekinaseremmers
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021* | 2022* | 2023* | |
|---|---|---|---|---|---|
| L01EB01 Gefitinib | 2.904.608 | 1.046.312 | 313.227 | 140.640 | 70.416 |
| L01EB02 Erlotinib | 6.144.019 | 2.759.137 | 614.927 | 201.710 | 196.463 |
| L01EB03 Afatinib | 3.337.922 | 2.115.895 | 1.545.271 | 1.430.391 | 1.442.588 |
| L01EB04 Osimertinib | 23.289.362 | 41.514.429 | 56.456.627 | 61.457.488 | 65.833.184 |
| Totaal | 35.675.910 | 47.435.773 | 58.930.051 | 63.230.229 | 67.542.651 |